株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

世界の全身麻酔薬市場:成長、動向、予測

Global General Anesthesia Drugs Market - Growth, Trends, and Forecasts (2017 - 2022)

発行 Mordor Intelligence LLP 商品コード 391430
出版日 ページ情報 英文 212 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=108.49円で換算しております。
世界の全身麻酔薬市場:成長、動向、予測 Global General Anesthesia Drugs Market - Growth, Trends, and Forecasts (2017 - 2022)
出版日: 2017年01月24日 ページ情報: 英文 212 Pages
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
概要

当レポートでは、世界の全身麻酔薬市場について調査し、市場の動向と今後の成長見通し、薬剤別、投与ルート別、地域別動向、および市場に参入する主要企業のプロファイルなどをまとめています。

第1章 イントロダクション

第2章 調査方法

第3章 エグゼクティブサマリー

第4章 主な推論

第5章 市場概要と業界動向

  • ポーターズファイブフォース

第6章 促進因子、阻害因子、機会、課題分析

  • 市場促進因子
  • 市場阻害因子
  • 市場の機会
  • 課題

第7章 市場セグメンテーション

  • 薬剤別
  • 投与ルート別
    • 吸入
    • 注入

第8章 地域別市場セグメンテーション

  • 北米
  • 欧州
  • アジア太平洋地域
  • 中東・アフリカ
  • 南米

第9章 競合環境

  • 新製品上市
  • 合併・買収
  • 協定、連携、提携

第10章 企業プロファイル

第11章 投資の機会に関するアナリストの見通し

第12章 市場の将来見通し

目次

Description

The global general anesthesia drugs market accounted for USD 3,840 million in 2015 and USD 3,983 million in 2016. The market is expected to reach USD 4,760 million by 2021, growing at a CAGR of 3.6% during the forecast period of 2016 to 2021. General anesthetic drugs suppress central nervous system activity and induce a complete lack of sensation.

Global General Anesthesia Drugs Market-Market Dynamics

The report details several factors driving and restraining the market, some of which are listed below.

Drivers

Growth in healthcare facilities in emerging economies

Advancement in surgical procedures

Increasing cosmetic and orthopedic surgeries

High incidence of emergency surgical procedures and critical care

New drug approval

Restraints

The side effects of general anesthetics, lack of skilled anesthesiologist and regulatory issues are turning out to restraints for the market.

The global general anesthesia drugs market has been segmented based on drugs and route of administration. The drugs section is further segmented based on the most used and popular drugs. This includes Sevoflurane, Propofol, Desflurane, isoflurane, Dexmedetomidine, Isoflurane, Midazolam and others. The segment based on the route of administration includes inhalation and injection. Propofol accounts for the largest market share in the global general anesthetic drugs market. Sevoflurane is the largest selling inhalational anesthetic drug. Sevoflurane is gradually replacing the use of Desflurane and Isoflurane.

The segmentation based on geography includes North America, Europe, Asia-Pacific, Middle East and Africa, and South America. North America has been subdivided into the USA, Canada, and Mexico. Europe has been subdivided into the UK, Germany, France, Italy, Spain, and Rest of Europe. The Asia-Pacific market has been subdivided into India, China, Japan, South Korea, Australia & New Zealand and Rest of Asia-Pacific. The Middle East and Africa market has been subdivided into GCC countries, South Africa and Rest of MENA. The South American market has been subdivided into Brazil, Argentina, and Rest of South America. North America accounted for the largest market share of nearly 32% in 2015 and is expected to have similar a market share during the forecast period. In the Asia-Pacific region, China accounted for the largest market share.

Some of the key players in the market are:

Abbott

Astra Zeneca

Baxter

Hospira

Novartis

Roche

What the Report Offers

Market analysis for the global general anesthesia drugs market, with region-specific assessments and competition analysis.

Market definition along with the identification of key drivers and restraints.

Identification of factors instrumental in changing the market scenario, rising prospective opportunities, and identification of key companies that can influence this market on a regional scale.

Extensively researched competitive landscape section with profiles of major companies along with their market share.

Identification and analysis of the macro and micro factors that affect the global general anesthesia drugs market.

A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information.

A wide-ranging knowledge and insights about the major players in this industry and the key strategies adopted by them to sustain and grow in the studied market.

Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped.

Table of Contents

1. Introduction

  • 1.1 Study deliverables
  • 1.2 Market definition
  • 1.3 Study assumptions

2. Research approach and methodology

  • 2.1 Introduction
  • 2.2 Analysis methodology
  • 2.3 Study timeline
  • 2.4 Study phases
    • 2.4.1 Secondary research
    • 2.4.2 Discussion guide
    • 2.4.3 Market engineering & econometric model
    • 2.4.4 Expert validation

3. Executive summary

4. Key inferences

5. Market overview and industry trends

  • 5.1 Current market scenario
  • 5.2 Porter's five forces
    • 5.2.1 Bargaining power of suppliers
    • 5.2.2 Bargaining power of consumers
    • 5.2.3 Threat to new entrants
    • 5.2.4 Threat to substitute products and services
    • 5.2.5 Competitive rivalry within the industry

6. Market drivers, restraints, challenges, and opportunities

  • 6.1 Market drivers
    • 6.1.1 Rising Number of Surgeries
    • 6.1.2 New approvals of anesthetic drugs
    • 6.1.3 Increase in number of cosmetic surgeries
  • 6.2 Market restraints
    • 6.2.1 Side effects of general anesthetics
    • 6.2.2 Lack of skilled anesthesiologist
    • 6.2.3 Regulatory Issues
  • 6.3 Market opportunities
  • 6.4 Market challenges

7. Market segmentation

  • 7.1 Drugs
    • 7.1.1 Propofol
    • 7.1.2 Sevoflurane
    • 7.1.3 Desflurane
    • 7.1.4 Isoflurane
    • 7.1.5 Dexmedetomidine
    • 7.1.6 Remifentanil
    • 7.1.7 Midazolam
    • 7.1.8 Others
  • 7.2 By route of administration
    • 7.2.1 Inhalation
    • 7.2.2 Injection

8. Market segmentation by geography

  • 8.1 North America
    • 8.1.1 United States
    • 8.1.2 Canada
    • 8.1.3 Mexico
  • 8.2 Europe
    • 8.2.1 Germany
    • 8.2.2 United Kingdom
    • 8.2.3 France
    • 8.2.4 Italy
    • 8.2.5 Spain
    • 8.2.6 Rest of Europe
  • 8.3 Asia-Pacific (APAC)
    • 8.3.1 China
    • 8.3.2 Japan
    • 8.3.3 India
    • 8.3.4 Australia & New Zealand
    • 8.3.5 South Korea
    • 8.3.6 Rest of Asia-Pacific
  • 8.4 Middle East & Africa
    • 8.4.1 GCC
    • 8.4.2 South Africa
    • 8.4.3 Rest of MENA
  • 8.5 South America
    • 8.5.1 Brazil
    • 8.5.2 Argentina
    • 8.5.3 Rest of South America

9. Competitive landscape

  • 9.1 Merger and acquisition analysis
  • 9.2 New Product Launches
  • 9.3 Agreements, Collaborations, and Partnerships

10. Company profiles

  • 10.1 Baxter
  • 10.2 Hospira
  • 10.3 Abbott
  • 10.4 Astra Zeneca
  • 10.5 Roche
  • 10.6 Novartis
  • 10.7 Pfizer
  • 10.8 Eisai
  • 10.9 Fresenius Se & Co.
  • 10.10 Hikma Pharmaceuticals

11. Future outlook for investment opportunity

12. Analyst outlook of the market